222 related articles for article (PubMed ID: 32344931)
1. Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.
Montironi R; Cimadamore A; Lopez-Beltran A; Scarpelli M; Aurilio G; Santoni M; Massari F; Cheng L
Cells; 2020 Apr; 9(5):. PubMed ID: 32344931
[TBL] [Abstract][Full Text] [Related]
2. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
5. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
Evans AJ; Humphrey PA; Belani J; van der Kwast TH; Srigley JR
Am J Surg Pathol; 2006 Jun; 30(6):684-93. PubMed ID: 16723845
[TBL] [Abstract][Full Text] [Related]
6. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
7. Aggressive variants of castration-resistant prostate cancer.
Beltran H; Tomlins S; Aparicio A; Arora V; Rickman D; Ayala G; Huang J; True L; Gleave ME; Soule H; Logothetis C; Rubin MA
Clin Cancer Res; 2014 Jun; 20(11):2846-50. PubMed ID: 24727321
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
Segawa N; Mori I; Utsunomiya H; Nakamura M; Nakamura Y; Shan L; Kakudo K; Katsuoka Y
Pathol Int; 2001 Jun; 51(6):452-9. PubMed ID: 11422807
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.
Gupta A; Wang Y; Browne C; Kim S; Case T; Paul M; Wills ML; Matusik RJ
Prostate; 2008 Jan; 68(1):50-60. PubMed ID: 18004726
[TBL] [Abstract][Full Text] [Related]
11. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
12. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
13. [Aggressive variants of castration resistant prostate cancer (CRPC): neuroendocrine prostate cancer.].
Quicios-Dorado C; Bolufer-Moragues E; Gomis-Goti C; Cabello-Benavente R; Cannata-Ortiz PJ; González-Enguita C
Arch Esp Urol; 2018 Sep; 71(8):721-734. PubMed ID: 30319132
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. [Neuroendocrine differentiation in prostate cancer: an unrecognized and therapy resistant phenotype].
Bonkhoff H; Fixemer T
Pathologe; 2005 Nov; 26(6):453-60. PubMed ID: 16195860
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
Aggarwal R; Zhang T; Small EJ; Armstrong AJ
J Natl Compr Canc Netw; 2014 May; 12(5):719-26. PubMed ID: 24812138
[TBL] [Abstract][Full Text] [Related]
17. Neuronal Trans-Differentiation in Prostate Cancer Cells.
Farach A; Ding Y; Lee M; Creighton C; Delk NA; Ittmann M; Miles B; Rowley D; Farach-Carson MC; Ayala GE
Prostate; 2016 Oct; 76(14):1312-25. PubMed ID: 27403603
[TBL] [Abstract][Full Text] [Related]
18. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
[TBL] [Abstract][Full Text] [Related]
19. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.
Abdulfatah E; Reichert ZR; Davenport MS; Chinnaiyan AM; Dadhania V; Wang X; Mannan R; Kunju LP; Hollenbeck BK; Montgomery JS; Kaffenberger SD; Morgan TM; Alva AS; Palapattu GS; Vaishampayan UN; Alumkal JJ; Spratt DE; Udager AM; Mehra R
Med Oncol; 2021 Feb; 38(3):26. PubMed ID: 33586037
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series.
Gopalan A; Al-Ahmadie H; Chen YB; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Fine SW
Histopathology; 2022 Aug; 81(2):246-254. PubMed ID: 35758203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
